AGPAT5在肝癌中的功能与机制研究

陈奕君; 刘雨航; 段海波; 王雄军

doi:10.19401/j.cnki.1007-3639.2024.09.004

您当前的位置：

首页 >

文章列表页 >

AGPAT5在肝癌中的功能与机制研究

论著 | 更新时间：2025-12-31

- AGPAT5在肝癌中的功能与机制研究
- Functional and mechanistic of AGPAT5 in liver cancer
- 中国癌症杂志 2024年34卷第9期页码：838-847
- 作者机构：
  
  广州大学精准编辑与健康研究中心，广东广州 510405
- 作者简介：
  
  [ "陈奕君（ORCID：0009-0004-2105-3387），硕士。" ]
  王雄军（ORCID：0000-0003-3946-5748），教授、博士研究生导师。
- 基金信息：
  
  国家自然科学基金面上项目(82272714)
- DOI：10.19401/j.cnki.1007-3639.2024.09.004
  中图分类号： R735.7
- 收稿：2024-04-20，
  
  修回：2024-09-09，
  
  纸质出版：2024-09-30
- 稿件说明：
移动端阅览
陈奕君, 刘雨航, 段海波, 等. AGPAT5在肝癌中的功能与机制研究[J]. 中国癌症杂志, 2024,34(9):838-847.

Yijun CHEN, Yuhang LIU, Haibo DUAN, et al. Functional and mechanistic of AGPAT5 in liver cancer[J]. China Oncology, 2024, 34(9): 838-847.
陈奕君, 刘雨航, 段海波, 等. AGPAT5在肝癌中的功能与机制研究[J]. 中国癌症杂志, 2024,34(9):838-847. DOI： 10.19401/j.cnki.1007-3639.2024.09.004.

Yijun CHEN, Yuhang LIU, Haibo DUAN, et al. Functional and mechanistic of AGPAT5 in liver cancer[J]. China Oncology, 2024, 34(9): 838-847. DOI： 10.19401/j.cnki.1007-3639.2024.09.004.

摘要

背景与目的：

肿瘤的发生、发展过程中会发生代谢重编程，1-酰基甘油-3-磷酸O-酰基转移酶（1-acylglycerol-3-phosphate O-acyltransferase，AGPAT）作为三酰甘油（triacylglycerol，TAG）从头合成的关键酶，与肿瘤的进展密切相关。但目前作为亚型之一的AGPAT5在癌症中的研究还十分有限，本研究深入剖析AGPAT5在肝癌发生、发展中发挥的作用及潜在的分子机制，旨在为肝癌诊断和治疗策略提供新思路。

方法：

利用慢病毒感染将多种肝癌细胞系中的

AGPAT

5敲减，并通过锥虫蓝计数、划痕、transwell及平板克隆等实验在体外检测AGPAT5对肝癌细胞增殖、迁移及抗失巢凋亡能力的影响。通过回复野生型或酶活性缺失型的AGPAT5，探究其作为代谢酶是否发挥经典代谢作用调控肝癌细胞迁移。构建BALB/c裸鼠尾静脉注射移植瘤模型，从体内层面验证体外的细胞表型。采用免疫沉淀质谱联用（immunoprecipitation mass spectrum，IP-MS）鉴定出与AGPAT5相互作用的蛋白，并进行免疫共沉淀（co-immunoprecipitation，coIP）验证。蛋白质翻译后通过修饰鉴定分析AGPAT5潜在的修饰位点，通过体外实验探究点突变前后对肝癌细胞迁移的影响。通过co

IP探究该位点突变前后AGPAT5与相互作用蛋白结合的情况。通过敲低相互作用蛋白确定其在细胞表型中的作用。通过回复实验验证AGPAT5是否通过相互作用蛋白发挥作用。检测野生型肝癌细胞系中的AGPAT5和相互作用蛋白的表达水平，检验两者之间是否具有相关性。

结果：

肝癌细胞敲减

AGPAT

5后会更加耐受无血清饥饿，并促进细胞迁移，但不会影响细胞增殖和失巢凋亡。而酶活性缺失并不影响AGPAT5对肝癌细胞迁移的抑制。敲减

AGPAT

5可促进肝癌细胞在裸鼠体内的肺转移和肝转移。AGPAT5可以与原纤维蛋白（fibrillarin，FBL）相互作用，并在无血清饥饿刺激下加强两者的结合。遏制FBL的表达会抑制肝癌细胞迁移，且效果与过表达AGPAT5相似。抑制FBL的表达可削弱敲低

AGPAT

5对肝癌细胞迁移的促进作用。在已检测的肝癌细胞系中，AGPAT5和FBL在蛋白水平上并不存在相关性。K201位点突变使AGPAT5对肝癌细胞迁移的抑制作用减弱，并使AGPAT5与FBL的结合减弱。

结论：

敲低

AGPAT

5能够显著提高肝癌细胞迁移能力。AGPAT5可以与FBL相互作用，在无血清饥饿刺激下，AGPAT5或通过K201位点的乙酰化加强与FBL的结合，从而更有效地遏制FBL，进而抑制肝癌细胞迁移。但这种抑制作用并非来自AGPAT5的代谢酶活性，而是由非代谢作用所驱动。

Abstract

Background and purpose:

Metabolic reprogramming occurs during tumor progression

and 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT)

as a key enzyme in the

de novo

synthesis of triacylglycerol (TAG)

is closely associated with tumor progression. However

one of the isoforms

AGPAT5

has been studied in cancer in a very limited way

and this study aimed to provide a new perspective on the role of AGPAT5 in hepatocellular carcinoma and its potential molecular mechanisms

providing novel ideas for the diagnosis and treatment strategies of liver cancer.

Methods:

AGPAT

5 was knocked down in a variety of hepatocellular carcinoma cell lines using lentiviral infection

and the effects of AGPAT5 on the functions of hepatocellular carcinoma cell proliferation

migration and resistance to anoikis were detected

in vitro

by experiments such as Taipan blue counting

scratching

transwell and plate cloning. The wild-type or enzyme activity-deficient form of

AGPAT

5 was rescued to investigate whether AGPAT5

as a metabolic enzyme

plays a classical role in regulating the migration of hepatocellular carcinoma cells. We constructed a tail vein metastasis model in nude mice to v

alidate the cellular phenotype

in vitro

from the

in vivo

level. Immunoprecipitation mass spectrum (IP-MS) identified proteins interacting with AGPAT5 and verified by co-immunoprecipitation (coIP). Protein post-translational modification identification was performed to analyze the potential modification sites of AGPAT5

and

in vitro

experiments were performed to explore the effects of the point mutation before and after the point mutation on the migration of hepatocellular carcinoma cells. CoIP was performed to explore the binding of AGPAT5 to the interacting protein before and after the mutation of the site. We determined its role in cell phenotype by knocking down interacting proteins. Rescue experiments were used to verify whether AGPAT5 exerts its effects through the interacting protein. We detected the expression levels of AGPAT5 and the interacting protein in wild-type hepatocellular carcinoma cell lines to examine their correlation.

Results:

Knockdown of

AGPAT

5 increased the tolerance to serum-free starvation and promoted hepatocellular carcinoma cell migration

but did not affect proliferation and anoikis. However

deletion of enzyme activity did not affect the inhibition of hepatocellular carcinoma cell migration by AGPAT5. Knockdown of

AGPAT

5 promoted lung and liver metastasis of hepatocellular carcinoma cells in nude mice. AGPAT5 could interact with fibrillarin (FBL)

and the interaction was strengthened under serum starvation conditions. Curbing FBL expression inhibited hepatocellular carcinoma cell migration

and the effect was similar to that of overexpression of AGPAT5. Inhibition of FBL expression weakened the promoting effect of

AGPAT

5 knockdown on hepatocellular carcinoma cell migration; In the hepatocellular carcinoma cell lines examined

AGPAT5 and FBL did not show any correlation at the protein level. The inhibitory effect of AGPAT5 on hepatocellular carcinoma cell migration was

attenuated by the K201 site mutation

and the K201 site mutation attenuated the binding of AGPAT5 to FBL.

Conclusion:

Knockdown of

AGPAT

5 can significantly enhance the migratory ability of hepatocellular carcinoma cells. AGPAT5 can interact with FBL

and in the absence of serum starvation stimulation

AGPAT5 strengthen its binding to FBL through acetylation of the K201 site

thereby more effectively inhibiting FBL

consequently inhibiting the migration of hepatocellular carcinoma cells. But this inhibitory effect is not derived from the metabolic enzyme activity of AGPAT5

but driven by non-metabolic function.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .

BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .

BUDNY A , KOZŁOWSKI P , KAMIŃSKA M , et al . Epidemiology and risk factors of hepatocellular carcinoma [J ] . Pol Merkur Lekarski , 2017 , 43 ( 255 ): 133 - 139 .

FORNER A , LLOVET J M , BRUIX J . Hepatocellular carcinoma [J ] . Lancet , 2012 , 379 ( 9822 ): 1245 - 1255 . DOI: 10.1016/S0140-6736(11)61347-0 http://doi.org/10.1016/S0140-6736(11)61347-0

TSILIMIGRAS D I , BRODT P , CLAVIEN P A , et al . Liver metastases [J ] . Nat Rev Dis Primers , 2021 , 7 ( 1 ): 27 . DOI: 10.1038/s41572-021-00261-6 http://doi.org/10.1038/s41572-021-00261-6

LEE Y T , GEER D A . Primary liver cancer: pattern of metastasis [J ] . J Surg Oncol , 1987 , 36 ( 1 ): 26 - 31 .

VALENTINE W J , YANAGIDA K , KAWANA H , et al . Update and nomenclature proposal for mammalian lysophospholipid acyltransferases, which create membrane phospholipid diversity [J ] . J Biol Chem , 2022 , 298 ( 1 ): 101470 .

KARAGIOTA A , CHACHAMI G , PARASKEVA E . Lipid metabolism in cancer: the role of acylglycerolphosphate acyltransferases (AGPATs) [J ] . Cancers , 2022 , 14 ( 1 ): 228 .

PRASAD S S , GARG A , AGARWAL A K . Enzymatic activities of the human AGPAT isoform 3 and isoform 5: localization of AGPAT5 to mitochondria [J ] . J Lipid Res , 2011 , 52 ( 3 ): 451 - 462 . DOI: 10.1194/jlr.M007575 http://doi.org/10.1194/jlr.M007575

VARGAS T , MORENO-RUBIO J , HERRANZ J , et al . ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-Ⅱ colon cancer patients [J ] . Oncotarget , 2015 , 6 ( 9 ): 7348 - 7363 .

NIESPOREK S , DENKERT C , WEICHERT W , et al . Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis [J ] . Br J Cancer , 2005 , 92 ( 9 ): 1729 - 1736 .

BLASKOVICH M A , YENDLURI V , LAWRENCE H R , et al . Lysophosphatidic acid acyltransferase beta regulates mTOR signaling [J ] . PLoS One , 2013 , 8 ( 10 ): e78632 .

DÓRIA M L , RIBEIRO A S , WANG J , et al . Fatty acid and phospholipid biosynthetic pathways are regulated throughout mammary epithelial cell differentiation and correlate to breast cancer survival [J ] . FASEB J , 2014 , 28 ( 10 ): 4247 - 4264 . DOI: 10.1096/fj.14-249672 http://doi.org/10.1096/fj.14-249672

ZHANG D P , SHI R C , XIANG W , et al . The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages [J ] . Signal Transduct Target Ther , 2020 , 5 ( 1 ): 24 .

SUMANTRAN V N , MISHRA P , SUDHAKAR N . Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression [J ] . Indian J Biochem Biophys , 2015 , 52 ( 2 ): 125 - 131 .

LI M , ZHAO Z W , ZHANG Y , et al . Over-expression of Ephb4 is associated with carcinogenesis of gastric cancer [J ] . Dig Dis Sci , 2011 , 56 ( 3 ): 698 - 706 .

SONG L , YANG J , DUAN P , et al . MicroRNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting LPAATβ [J ] . Arch Biochem Biophys , 2013 , 535 ( 2 ): 128 - 135 .

YANG J F , XIANG C P , LIU J M . Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection [J ] . Scand J Clin Lab Invest , 2021 , 81 ( 1 ): 39 - 45 . DOI: 10.1080/00365513.2020.1852478 http://doi.org/10.1080/00365513.2020.1852478

ZANG J , SUN J J , XIU W C , et al . Low expression of AGPAT5 is associated with clinical stage and poor prognosis in colorectal cancer and contributes to tumour progression [J ] . Clin Med Insights Oncol , 2022 , 16 : 11795549221137399 .

YING Q , ANSONG E , DIAMOND A M , et al . Abstract 1197: Selenium-binding protein 1-mediated tumor suppression is associated with alterations of lipid/glucose metabolic pathways in vivo [J ] . Cancer Res , 2015 , 75 ( 15_Supplement ): 1197 .

WEN P Z , WANG R , XING Y Q , et al . The prognostic value of the GPAT/AGPAT gene family in hepatocellular carcinoma and its role in the tumor immune microenvironment [J ] . Front Immunol , 2023 , 14 : 1026669 .

FAUBERT B , SOLMONSON A , DEBERARDINIS R J . Metabolic reprogramming and cancer progression [J ] . Science , 2020 , 368 ( 6487 ): eaaw5473 .

MARTIN-PEREZ M , URDIROZ-URRICELQUI U , BIGAS C , et al . The role of lipids in cancer progression and metastasis [J ] . Cell Metab , 2022 , 34 ( 11 ): 1675 - 1699 .

ZHANG Q , YAO D Q , RAO B , et al . The structural basis for the phospholipid remodeling by lysophosphatidylcholine acyltransferase 3 [J ] . Nat Commun , 2021 , 12 ( 1 ): 6869 . DOI: 10.1038/s41467-021-27244-1 http://doi.org/10.1038/s41467-021-27244-1

ZHU H W , YU H , ZHOU H , et al . Elevated nuclear PHGDH synergistically functions with cMyc to reshape the immune microenvironment of liver cancer [J ] . Adv Sci , 2023 , 10 ( 17 ): e2205818 .

YU H , SHI T Z , YAO L L , et al . Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion [J ] . Cell Mol Immunol , 2023 , 20 ( 8 ): 867 - 880 . DOI: 10.1038/s41423-023-01048-3 http://doi.org/10.1038/s41423-023-01048-3

MARCEL V , GHAYAD S E , BELIN S , et al . p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer [J ] . Cancer Cell , 2013 , 24 ( 3 ): 318 - 330 . DOI: 10.1016/j.ccr.2013.08.013 http://doi.org/10.1016/j.ccr.2013.08.013

SUN X R , GAO C W , XU X , et al . FBL promotes cancer cell resistance to DNA damage and BRCA1 transcription via YBX1 [J ] . EMBO Rep , 2023 , 24 ( 9 ): e56230 .

LIU Y Z , SHI Q L , LIU Y F , et al . Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer [J ] . Cancer Lett , 2024 , 602 : 217190 .

ZHANG J , YANG G , LI Q , et al . Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma [J ] . Oncol Lett , 2021 , 21 ( 2 ): 92 . DOI: 10.3892/ol.2020.12353 http://doi.org/10.3892/ol.2020.12353

浏览量

1506

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据